The objective of this study is to develop and validate dementia risk prediction models for mid- and late-life individuals that are based on accessible variables within a primary care setting. Using the Korean National Health Insurance Service database (2010-2019), we analyzed 6,696,073 individuals aged 40 and older who participated in a national health screening program over a mean follow-up of 8.95 years. Potential predictors were selected based on a literature review and the available data. Dementia cases were identified using claim-based codes and validated by corresponding prescription information. 5-year dementia risk prediction models for mid-life (40-59 years), and late-life (60+ years) stages were developed using the Cox proportional hazards model. Model performance was assessed through discrimination and calibration. Both models included age, sex, body mass index, smoking, alcohol consumption, physical activity, diabetes, hypertension, dyslipidemia, and chronic kidney disease. The models' AUROCs were 0.764 for mid-life and 0.743 for late-life. The impact of predictors on dementia risk was consistently stronger in mid-life than in late-life stages. Our models showed good calibration with low-risk estimates in mid-life and overall in late-life. These findings underscore the crucial role of managing modifiable risk factors, particularly during mid-life to reduce dementia risk.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.psychres.2024.116237 | DOI Listing |
J Neurol Sci
December 2024
Department of Neurology, University of California, San Francisco, USA.
This study examines the relationship between comorbid seizures and dementia among stroke patients using the 2017 Nationwide Inpatient Sample (NIS), the largest publicly available inpatient healthcare database in the United States. We analyzed data from 128,341 stroke patients, including those with ischemic and hemorrhagic strokes, to determine the prevalence of seizures and dementia, and the association between these conditions. Our findings reveal that 7.
View Article and Find Full Text PDFSports Med
December 2024
Australian Catholic University, North Sydney, NSW, Australia.
Geroscience
December 2024
Department of Kinesiology, The Pennsylvania State University, University Park, USA.
Metabolic syndrome (MetS) has been linked to accelerated cognitive decline and Alzheimer's disease and related dementias (ADRDs) via cerebral small vessel disease (CSVD); however, this relation in MetS without overt cardiometabolic disease comorbidities is unknown and may represent a population amenable to preventative strategies. Our study aimed to determine risk profiles for neurocognitive decline and ADRDs in early-stage MetS with evidence of CSVD using the TriNetX electronic health records (EHR) research network. Patients aged 50 to 80 years old meeting MetS criteria were identified utilizing TriNetX data from 76 healthcare organizations.
View Article and Find Full Text PDFAm J Geriatr Psychiatry
December 2024
Department of Neurology (HL, BHK, EHL, DS, HY, SWS, JPK), Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; Alzheimer's Disease Convergence Research Center (HL, BHK, EHL, DS, HY, SWS, JPK), Samsung Medical Center, Seoul, Republic of Korea; Neuroscience Center (EHL, DS, SWS, JPK), Samsung Medical Center, Seoul, Republic of Korea. Electronic address:
Objective: Brain atrophy measured by structural imaging has been used to quantify resilience against neurodegeneration in Alzheimer's disease. Considering glucose hypometabolism is another marker of neurodegeneration, we quantified metabolic resilience (MR) based on Fluorodeoxyglucose positron emission tomography (FDG PET) and investigated its clinical implications.
Methods: We quantified the MR and other resilience metrics, including brain resilience (BR) and cognitive resilience (CR), using partial least squares path modeling from the ADNI database.
Med Sci (Paris)
December 2024
Centre de recherche Bordeaux Population Health, Inserm U1219, institut de santé publique, d'épidémiologie et de développement, université de Bordeaux, Bordeaux, France.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!